Several pharmaceutical companies such as Johnson & Johnson (NYSE: JNJ), Merck (NYSE: MRK) , and Bayer (NYSE: have been taking steps to infuse their pipelines with new drug drugs by developing incubators to identify life science innovations that fit in with their longterm goals. Now Celgene (NASDAQ: CELG) is collaborating with a biotech incubator backed by early stage life science and healthcare investor Versant Ventures, according to a company statement.
The Toronto-based incubator, Blueline Bioscience, works with academic and medical research centers in Canada to fund and develop early-stage biotechnology companies. The collaboration will give a Celgene affiliate certain option rights for research in areas of joint strategic interest such as oncology and inflammation.
Image Courtesy of renjith krishnan / FreeDigitalPhotos.net
